ABSTRACT
INTRODUCTION
Dural arteriovenous fistulas (DAVFs) are abnormal vascular shunts between the dural arteries and dural venous sinuses. They can occur anywhere along the intracranial dura mater, although they are most frequently found involving the transverse, cavernous, and superior sagittal sinuses and the tentorium cerebelli.
1,2
The exact incidence is unknown, but DAVFs account for 10% to 15% of intracranial arteriovenous malformations. 3 Whereas some cases of DAVFs may remain clinically silent, some may involute spontaneously 4 or present with different symptoms.
Before the mid-1970s, DAVFs were thought to be congenital in origin. In the late 1970s, an acquired aetiology of DAVFs was proposed. 5 Since then, different aetiologies have been postulated, including venous sinus thrombosis, prior head trauma or transcranial surgery, hormonal influences (e.g. pregnancy, use of oral contraceptives) that may affect angiogenesis, tumours (causing obstructing of dural venous outflow), and prior ear infection. 6 In 1995, Cognard et al 7 and Borden et al 8 proposed that DAVFs are not benign lesions, and the clinical aggressiveness of DAVFs depends on the degree of cortical venous reflux (CVR). The Cognard and Borden classifications of DAVFs are the most commonly used, and both emphasise the importance of site of venous drainage and the presence of CVR.
As described by Borden and Cognard, the lack of cortical venous drainage (Borden Type I, Cognard types I, IIa) is a favourable feature for DAVFs and these cases are associated with a benign natural history. 7, 8 There is a low risk of conversion of type I DAVFs into higher grade, and a low risk of intracranial haemorrhage or death. 9, 10 In contrast, for DAVFs with CVR, the reported annual risks of non-haemorrhagic neurological deficits, intracranial haemorrhage, and mortality are up to 10%.
6,10
The presence of CVR is considered the most important determinant for management.
11 These patients may present with aggressive symptoms such as intracranial haemorrhage or neurological deficits. Other intolerable symptoms that may warrant treatment such as bruit, severe headache, seizures, and neuropsychiatric
率。由於DAVF是一種涉及不同嚴重程度和位置的疾病，因此治療方法應高度個性化，採用多學科 方法對每位患者進行個體化治療。 symptoms have also been reported.
2
Weighing the risk of treatment and natural history of DAVFs, most studies advocate treatment for highgrade lesion to avoid risks of haemorrhage and nonhaemorrhagic neurological defects. Low-grade lesions with debilitating symptoms (such as severe visual symptoms or tinnitus) may also be considered candidates for therapy.
In the past, DAVFs have been treated with many different approaches. Recent studies have shown an increased success rate of transcatheter embolisation, which can achieve a high occlusion rate, and is now considered as one of the primary treatment modality. In this paper, we present our preliminary experience in combined use of transvenous Onyx 18 and GDCs in treatment of intracranial DAVFs. The techniques, angiographic and clinical outcomes are discussed. We aimed to share our experience and provide a foundation for future studies to be performed for improving patient care.
METHODS

Patients
We retrospectively analysed all patients with DAVFs treated with combined use of Onyx 18 and GDCs performed in the same embolisation session, who were treated in our institution between 2014 and 2015. Five consecutive patients (three men and two women; mean age 37.2 years, range 23-60 years) were recruited. All DAVF shunts were located along the venous sinus wall or tentorial bridging vein with non-direct and non-exclusive leptomeningeal venous reflux, and retained venous sinus antegrade flow (Cognard classification type IIb). Two of these patients received prior embolisation treatment (one with transarterial Onyx, one with transarterial NBCA) but they presented with persistent symptoms related to residual DAVFs. The main presenting symptoms included: headache (n=4, 80%), seizure (n=2, 40%), visual symptoms (n=2, 40%), altered mental status due to underlying intraventricular haemorrhage (n=1, 20%), and pulsatile scalp mass (n=1, 20%). The baseline characteristics of the patients are summarised in Table 1 .
Pretreatment angiography, including selective bilateral external and internal carotid arteries digital subtraction angiographies, were performed for diagnosis and classification of the intracranial DAVFs.
Embolisation Procedures
Embolisation procedures were performed in our endovascular operating room with biplanar digital subtraction angiography facilities. Each patient was put Abbreviations: ACA = anterior cerebral artery; DAVF = dural arteriovenous fistula; ECA = external carotid artery; ICA = internal carotid artery; MMA = middle meningeal artery; mRS = modified Rankin Scale; STA = superficial temporal artery; VA = vertebral artery.
under general anaesthesia. Intravenous heparin bolus followed by infusion was given to maintain an activated clotting time of between 200 and 300 s. The right common femoral artery was catheterised with a 5F arterial sheath. The artery supplying the DAVF was cannulated by a 5F diagnostic catheter for arterial control. The DAVF outflow venous tracts and target venous sinuses were first embolised with GDCs (Target ® 360 coils, Stryker Neurovascular). Onyx vials were preprepared by placing on an Onyx shaker for 20 minutes prior to use. Onyx was aspirated into the Onyx Delivery Syringe and attached to the Syringe Catheter Interface Adaptor (SCIFA; ev3 Endovascular Inc., Plymouth [MN], US). DMSO was used to fill the catheter dead space. The SCIFA was then attached to the catheter hub, and pre-prepared Onyx 18 (6% ethylene vinyl alcohol) was slowly injected into the DAVFs in a controlled manner, under biplane road-mapping technique with fluoroscopic guidance. This allows direct visualisation of filling of the venous side of the DAVF. The Onyx injection was stopped when the DAVFs venous outflow tract was completely embolised, or there was persistent Onyx reflux into the distal venous sinus.
A post-embolisation angiogram was performed via the artery control catheter. All catheters were removed, and heparin infusion was discontinued and reversed with protamine at the end of the procedure.
Follow-up digital subtraction angiography at 6 months postoperatively was performed to assess the degree of residual arteriovenous shunting and presence of CVR. Cases with residual DAVF were reassessed with digital subtraction angiography at 18 months postoperatively.
Patients clinical outcomes were evaluated using the modified Rankin Scale.
RESULTS
Successful embolisation of the DAVF venous outflow and involved venous sinuses was achieved in all five cases. There was no non-target embolisation.
Among the five cases, complete obliteration (total disappearance of arteriovenous shunting) of the DAVFs were achieved in two (40%) cases, and neartotal occlusion (significant reduction of arteriovenous shunting with a small residual shunt) in one (20%) case, in single-stage embolisation procedure. In the other two (40%) cases, near-total occlusion of the DAVF was achieved after two separate sessions of embolisation with slow flow residual arteriovenous shunt (Figures 1  and 2 ). All patients reported symptom alleviation after the procedure(s).
The angiographic findings of DAVF location, total volume of Onyx injected, coil volume, angiographic and clinical outcome were summarised in Table 2 . In all five cases, no residual CVR was observed on follow-up angiogram. No fistula recanalisation was observed at 6-or 18-month follow-up angiography. There were no reported cases of new neurological deficits after the procedure(s). There were no reported cases of unintentional reflux of Onyx 18 into the normal vasculature. Results from other case series are summarised and compared with the those from the present study in Table 3 .
15,17-19
DISCUSSION
Many different approaches have been used to treat DAVFs, including conservative treatment, 4 gamma knife surgery, 20 surgery, 21 transarterial or transvenous catheter embolisation, 19 or a combination of these techniques. The main aim of current endovascular treatments for DAVFs is to completely obliterate the arteriovenous shunt, which can be achieved via a transarterial or transvenous approach. 20 
Oh et al
5 reported nine patients undergoing conservative treatment of cavernous sinus DAVF, in which three patients showed complete obliteration. The other six developed new or recurrent symptoms. Conservative treatment could be considered in cases with a benign natural history (Borden Type I, or Cognard types I or IIa), and when treatment risks outweigh the potential benefits. In these cases, the aim of treatment would be clinical improvement rather than complete angiographic cure. However, if patients present with progressive neurological symptoms, more aggressive treatment should be considered even for benign types of DAVFs.
Studies have reported high success rate (up to 87%) of complete occlusion of DAVFs with the use of gamma knife surgery. 22 However, compared with endovascular treatment, which provides an immediate effect, gamma knife surgery has a latent period of up to 3 years before treatment effects are observed. Such delay is considered unacceptable in DAVFs with CVR, as these lesions are prone to bleeding during this latent period.
Wachter et al
21 reported different surgical approaches of treatment of DAVFs, with a high success rate for direct interrupting of the draining vein for non-sinustype DAVFs. However, those authors also demonstrated comparable treatment outcomes between surgery and endovascular embolisation for sinus-type DAVFs, with the latter favoured for their lower complication rate.
21
The transarterial approach requires superselective catheterisation of the arterial feeders. This method is particularly useful when the fistula site involves severely stenotic venous outflow or isolated venous sinus. However, many cases of DAVFs present with multiple small feeders derived from external and internal carotid arteries, which are mostly small fine and tortuous vessels. This makes the transarterial approach extremely difficult, if not impossible. 23, 24 Even with successful superselective catheterisation of the small arterial feeders, there is still a high risk of retrograde reflux or migration of liquid embolic agent into arterialised draining veins, which may cause subsequent venous infarction. In these cases, the transvenous approach is considered safer when the diseased sinus segment can be completely occluded, as long as the diseased segment has minimal contributions to the normal venous drainage.
Transvenous embolisation involves retrograde catheterisation of the involved dural venous sinus or the cortical veins, followed by obliteration of the arteriovenous shunt by use of liquid embolic agents and/ or coils. Previous studies have suggested obliteration of the fistula site solely with coils; however, complications such as postoperative cranial nerve palsy have been reported. 25 Furthermore, despite dense packing of coils, residual fistulas may still occur. Therefore, in our cases, we first deployed detachable coils into the venous outflow, and followed by slow injection of Onyx 18. By first employing coils and then Onyx injection, the coils achieved initial flow reduction within the venous channels and form a scaffold for Onyx cast anchorage. The use of Onyx enables infiltration into the fistula site and smaller total volume of coils required. 26 Long et al 26 described their initial experience in the combined use of transvenous Onyx 18 together with coils in treatment of cavernous sinus DAVFs in eight cases. That study demonstrated promising results for the combined transvenous use of Onyx 18 and detachable coils in the management of cavernous sinus DAVFs; however, that technique for management of non-cavernous sinuses DAVFs has not been reported.
The use of Onyx involves some risks. The slow injection rate of Onyx implies a prolonged fluoroscopic time, where potential radiation-induced complications may occur.
27,28
Other complications have also been reported, including cranial nerve injury, catheter entrapment, rupture, and vasospasm due to angiotoxicity caused by both Onyx 18 and DMSO. [27] [28] [29] [30] The risk of catheter entrapment can be avoided by positioning the catheter tip in a relatively straight vessel segment to avoid reflux around the catheter tip, although this is not always technically feasible. DMSO-induced angiotoxicity and vasospasm Abbreviation: NBCA = n-butyl cyanoacrylate.
can also be prevented by slow Onyx injection, 27 at a cost of prolonged operation time. One possible limitation of Onyx is that there are limited numbers of DMSOcompatible delivery systems available for clinical use.
30
Onyx-related complications may also affect the success of this approach. For instance, large amounts of Onyx and DMSO may be required and complications related to this are possible. Furthermore, reflux of Onyx distally into normal venous sinuses will affect the treatment endpoint.
Our study has some limitations. We performed our new approach in only five patients; generalisation of this treatment approach requires further evaluation. Another limitation is that our approach was performed in only selected patients where the transarterial approach was considered extremely difficult or not feasible; thus, exact comparison of the current approach with the transarterial approach is impossible.
Compared with our prior experience of transarterial embolisation, we noticed an increased rate of complete or near-complete occlusion of the shunting using our new approach. Between 2008 and 2013 we performed 12 embolisation operations for DAVFs using the transarterial approach (4 with NBCA and 8 with Onyx 18). Of them, only seven (58%) cases were able to achieve complete or near-complete occlusion, owing to the presence of multiple small and tortuous arterial feeders not-accessible by microcatheters and microguidewires.
CONCLUSION
Onyx 18 in combination with GDCs using a transvenous approach is a safe and feasible method for treating DAVFs, with a reasonably high success rate in a small sample. With our preliminary experience, we aim to improve outcome for patients with DAVF. As DAVF is a spectrum of diseases with different severities and locations, treatment approaches should be highly individualised, and a multidisciplinary approach should be adopted for treatment for each patient. Future study is recommended for selected cases where both transarterial and transvenous approaches are considered technically feasible, to compare the success rate of each modality.
